Mechanism of action of the biologics used in the treatment of plaque psoriasis

The biologics modified the treatment of plaque psoriasis in recent years. It is important that dermatologists know the mechanism of action of these drugs so they can better understand their indications and side effects. In this article we will discuss the mechanism of action of five biologics used in the treatment of plaque psoriasis: three anti-tumour necrosis factor agents (infliximab, adalimumab and etanercept) and two interleukin inhibitors (ustekinumab and secukinumab).

• Publication year

  2017

• Venue

  Journal of Clinical Research

• Publication date

  2017-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.15226/2378-1726/4/1/00150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study

  2017influential reference
• The Inflammatory Response in Psoriasis: a Comprehensive Review

  2016influential reference
• Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.

  2015cited by this paper
• Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

  2015influential reference
• Biologics in dermatology: adverse effects

  2015influential reference
• Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

  2014influential reference
• Efficacy of biologics in the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis of randomized controlled trials with different time points

  2014cited by this paper
• Spotlight on Ustekinumab in Moderate To Severe Plaque Psoriasis

  2012influential reference
• Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

  2011cited by this paper
• Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

  2011influential reference
• Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.

  2010influential reference
• Transmembrane TNF-α: structure, function and interaction with anti-TNF agents

  2010influential reference

• No citing papers are available for this paper.